IMMUNOVIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.652 SEK | -4.73% |
|
-11.28% | -6.77% |
| Apr. 29 | Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024 | |
| Apr. 29 | Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.14M 106K | Sales 2023 | 1.58M 145K | Capitalization | 80.25M 7.4M |
|---|---|---|---|---|---|
| Net income 2022 | -168M -15.49M | Net income 2023 | -309M -28.5M | EV / Sales 2022 | 460 x |
| Net cash position 2022 | 68.47M 6.31M | Net cash position 2023 | 72.5M 6.69M | EV / Sales 2023 | 4.92 x |
| P/E ratio 2022 |
-3.54
x | P/E ratio 2023 |
-0.22
x | Employees | 11 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on Immunovia AB
More press releases
| 1 day | -4.73% | ||
| 1 week | -11.28% | ||
| Current month | -18.62% | ||
| 1 month | -2.59% | ||
| 3 months | +1.60% | ||
| 6 months | -30.30% | ||
| Current year | -6.77% |
1 week
1.63
1.90
1 month
1.532.60
Current year
1.153.00
1 year
0.514.73
3 years
0.51141.50
5 years
0.51298.50
10 years
0.51298.50
| Managers | Title | Age | Since |
|---|---|---|---|
Jeff Borcherding
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | 62 | 22-03-31 | |
Karl Stone
COO | Chief Operating Officer | 61 | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 16-12-08 | |
Peter Andersen
CHM | Chairman | 67 | 19-12-31 |
Michael Löfman
BRD | Director/Board Member | - | 23-05-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.652 | -4.73% | 387,401 |
| 24-05-08 | 1.734 | -3.88% | 99,225 |
| 24-05-07 | 1.804 | -0.33% | 144,300 |
| 24-05-06 | 1.81 | -2.79% | 182,387 |
Delayed Quote Nasdaq Stockholm, May 10, 2024 at 11:29 am EDT
More quotes
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunoviaâs test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Calendar
2024-06-04
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -6.77% | 6.9M | |
| -16.33% | 18.62B | |
| -42.18% | 2.85B | |
| +22.02% | 1.94B | |
| +0.39% | 1.68B | |
| +27.15% | 1.26B | |
| -10.70% | 1.03B | |
| -18.27% | 938M | |
| +0.66% | 783M | |
| -25.07% | 628M |
- Stock Market
- Equities
- IMMNOV Stock
